The implication of neuroactive steroids in tourette's syndrome pathogenesis: A role for 5α-reductase?

Journal of Neuroendocrinology

Volumn 25, Issue 11, 2013, Pages 1196-1208

  Bortolato, M ^a   Frau, R ^b   Godar, S C ^a   Mosher, L J ^a   Paba, S ^b   Marrosu, F ^b   Devoto, P ^b  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Androgens; Dopamine; Neuroactive steroids; Steroids

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ANDROGEN; ANDROSTENEDIONE; CYTOCHROME B5; DOPAMINE; FINASTERIDE; FLUTAMIDE; GLUCOCORTICOID; LUTEINIZING HORMONE; NEUROSTEROID; NEUROTRANSMITTER; PRASTERONE; STEROID 17ALPHA MONOOXYGENASE; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2; TESTOSTERONE 17BETA DEHYDROGENASE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CHOLESTENONE 5ALPHA REDUCTASE;

ADRENAL CORTEX; ADRENARCHE; ANDROGEN SYNTHESIS; ATTENTION DEFICIT DISORDER; AUTISM; BETA HEMOLYTIC STREPTOCOCCUS; CHROMOSOME 2P; CHROMOSOME 2P23; CONTROLLED CLINICAL TRIAL (TOPIC); CORPUS STRIATUM; DEPRESSION; DEVELOPMENTAL STAGE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; ENVIRONMENTAL STRESS; ENZYME ACTIVITY; EXTRAPYRAMIDAL SYMPTOM; GENE; GENETIC ASSOCIATION; GENETIC LINKAGE; GILLES DE LA TOURETTE SYNDROME; HUMAN; IMPOTENCE; IMPULSE CONTROL DISORDER; INTRAUTERINE INFECTION; LIVER DISEASE; MATERNAL SMOKING; MENSTRUAL CYCLE; MENTAL STRESS; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; ONSET AGE; PREVALENCE; PRIORITY JOURNAL; PUBERTY; REVIEW; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SLITRK1 GENE; STEROIDOGENESIS; SUICIDAL IDEATION; TIC; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; FEMALE; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; MALE; METABOLISM; PHYSIOLOGY; TOURETTE SYNDROME;

ANDROGENS; CHOLESTENONE 5 ALPHA-REDUCTASE; FEMALE; GENE-ENVIRONMENT INTERACTION; HUMANS; MALE; NEUROTRANSMITTER AGENTS; SEX FACTORS; TOURETTE SYNDROME;

EID: 84881522272     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/jne.12066     Document Type: Review

References (165)

1. Albin RL, Mink JW. Recent advances in Tourette syndrome research. Trends Neurosci 2006; 29: 175-182.
2. Singer HS. Tourette's syndrome: from behaviour to biology. Lancet Neurol 2005; 4: 149-159.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, DC. American Psychiatric Publishing, Inc., 2000.
4. Robertson MM. The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 1: the epidemiological and prevalence studies. J Psychosom Res 2008; 65: 461-472.
5. Ghanizadeh A, Mosallaei S. Psychiatric disorders and behavioral problems in children and adolescents with Tourette syndrome. Brain Dev 2009; 31: 15-19.
6. Frank MC, Piedad J, Rickards H, Cavanna AE. The role of impulse control disorders in Tourette syndrome: an exploratory study. J Neurol Sci 2011; 310: 276-278.
7. Jankovic J. Tourette syndrome. Phenomenology and classification of tics. Neurol Clin 1997; 15: 267-275.
8. Jankovic J. Tourette's syndrome. N Engl J Med 2001; 345: 1184-1192.
9. Jankovic J. Diagnosis and classification of tics and Tourette syndrome. Adv Neurol 1992; 58: 7-14.
10. Kwak C, Dat Vuong K, Jankovic J. Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord 2003; 18: 1530-1533.
11. Huey ED, Zahn R, Krueger F, Moll J, Kapogiannis D, Wassermann EM, Grafman J. A psychological and neuroanatomical model of obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 2008; 20: 390-408.
12. Robertson MM. Gilles de la Tourette syndrome: the complexities of phenotype and treatment. Br J Hosp Med 2011; 72: 100-107.
13. Leckman JF, Zhang H, Vitale A, Lahnin F, Lynch K, Bondi C, Kim YS, Peterson BS. Course of tic severity in Tourette syndrome: the first two decades. Pediatrics 1998; 102: 14-19.
14. Singer HS, Walkup JT. Tourette syndrome and other tic disorders. Diagnosis, pathophysiology, and treatment. Medicine 1991; 70: 15-32.
15. Cohen SC, Leckman JF, Bloch MH. Clinical assessment of Tourette syndrome and tic disorders. Neurosci Biobehav Rev 2013; 37: 997-1007.
16. Kalanithi PS, Zheng W, Kataoka Y, DiFiglia M, Grantz H, Saper CB, Schwartz ML, Leckman JF, Vaccarino FM. Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome. Proc Natl Acad Sci USA 2005; 102: 13307-13312.
17. Kataoka Y, Kalanithi PS, Grantz H, Schwartz ML, Saper C, Leckman JF, Vaccarino FM. Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome. J Comp Neurol 2010; 518: 277-291.
18. Mink JW. Neurobiology of basal ganglia circuits in Tourette syndrome: faulty inhibition of unwanted motor patterns? Adv Neurol 2001; 85: 113-122.
19. Leckman JF, Bloch MH, Smith ME, Larabi D, Hampson M. Neurobiological substrates of Tourette's disorder. J Child Adolesc Psychopharmacol 2010; 20: 237-247.
20. Roessner V, Schoenefeld K, Buse J, Bender S, Ehrlich S, Munchau A. Pharmacological treatment of tic disorders and Tourette syndrome. Neuropharmacology 2013; 68: 143-149.
21. Shale H, Fahn S, Mayeux R. Tics in a patient with Parkinson's disease. Mov Disord 1986; 1: 79-83.
22. Stern E, Silbersweig DA, Chee KY, Holmes A, Robertson MM, Trimble M, Frith CD, Frackowiak RS, Dolan RJ. A functional neuroanatomy of tics in Tourette syndrome. Arch Gen Psychiatry 2000; 57: 741-748.
23. Minzer K, Lee O, Hong JJ, Singer HS. Increased prefrontal D2 protein in Tourette syndrome: a postmortem analysis of frontal cortex and striatum. J Neurol Sci 2004; 219: 55-61.
24. Gilbert DL, Christian BT, Gelfand MJ, Shi B, Mantil J, Sallee FR. Altered mesolimbocortical and thalamic dopamine in Tourette syndrome. Neurology 2006; 67: 1695-1697.
25. Steeves TD, Ko JH, Kideckel DM, Rusjan P, Houle S, Sandor P, Lang AE, Strafella AP. Extrastriatal dopaminergic dysfunction in tourette syndrome. Ann Neurol 2010; 67: 170-181.
26. Buse J, Schoenefeld K, Munchau A, Roessner V. Neuromodulation in Tourette syndrome: dopamine and beyond. Neurosci Biobehav Rev 2013; 37: 1069-1084.
27. Wong DF, Brasic JR, Singer HS, Schretlen DJ, Kuwabara H, Zhou Y, Nandi A, Maris MA, Alexander M, Ye W, Rousset O, Kumar A, Szabo Z, Gjedde A, Grace AA. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology 2008; 33: 1239-1251.
28. Gilbert D, Budman C, Singer H, Kurlan R, Kwan R, Chipkin R. Interim analysis of an open-label, multi-center study of ecopipam, a dopamine D1 receptor antagonist, for tic reduction in adults with Tourette syndrome. Neurology 2013; 80: P02.058.
29. Berns GS, Sejnowski TJ. A computational model of how the basal ganglia produce sequences. J Cogn Neurosci 1998; 10: 108-121.
30. Suri RE, Schultz W. Learning of sequential movements by neural network model with dopamine-like reinforcement signal. Exp Brain Res 1998; 121: 350-354.
31. Swerdlow NR, Karban B, Ploum Y, Sharp R, Geyer MA, Eastvold A. Tactile prepuff inhibition of startle in children with Tourette's syndrome: in search of an "fMRI-friendly" startle paradigm. Biol Psychiatry 2001; 50: 578-585.
32. Hikosaka O, Nakamura K, Sakai K, Nakahara H. Central mechanisms of motor skill learning. Curr Opin Neurobiol 2002; 12: 217-222.
33. Seymour B, O'Doherty JP, Dayan P, Koltzenburg M, Jones AK, Dolan RJ, Friston KJ, Frackowiak RS. Temporal difference models describe higher-order learning in humans. Nature 2004; 429: 664-667.
34. Castellanos F, Giedd J, Hamburger S, Marsh W, Rapoport J. Brain morphometry in Tourette's syndrome The influence of comorbid attention-deficit/hyperactivity disorder. Neurology 1996; 47: 1581-1583.
35. Swerdlow NR, Young AB. Neuropathology in Tourette syndrome: an update. Adv Neurol 2001; 85: 151-161.
36. Marsh R, Alexander GM, Packard MG, Zhu H, Wingard JC, Quackenbush G, Peterson BS. Habit learning in Tourette syndrome: a translational neuroscience approach to a developmental psychopathology. Arch Gen Psychiatry 2004; 61: 1259-1268.
37. Palminteri S, Lebreton M, Worbe Y, Hartmann A, Lehericy S, Vidailhet M, Grabli D, Pessiglione M. Dopamine-dependent reinforcement of motor skill learning: evidence from Gilles de la Tourette syndrome. Brain 2011; 134: 2287-2301.
38. Deng H, Gao K, Jankovic J. The genetics of Tourette syndrome. Nat Rev Neurol 2012; 8: 203-213.
39. Paschou P. The genetic basis of Gilles de la Tourette syndrome. Neurosci Biobehav Rev 2013; 37: 1026-1039.
40. Hoekstra PJ, Dietrich A, Edwards MJ, Elamin I, Martino D. Environmental factors in Tourette syndrome. Neurosci Biobehav Rev 2013; 37: 1040-1049.
41. Kidd KK, Prusoff BA, Cohen DJ. Familial pattern of Gilles de la Tourette syndrome. Arch Gen Psychiatry 1980; 37: 1336-1339.
42. Pauls DL, Cohen DJ, Heimbuch R, Detlor J, Kidd KK. Familial pattern and transmission of Gilles de la Tourette syndrome and multiple tics. Arch Gen Psychiatry 1981; 38: 1091-1093.
43. Abelson JF, Kwan KY, O'Roak BJ, Baek DY, Stillman AA, Morgan TM, Mathews CA, Pauls DL, Rasin MR, Gunel M, Davis NR, Ercan-Sencicek AG, Guez DH, Spertus JA, Leckman JF, Dure LSt, Kurlan R, Singer HS, Gilbert DL, Farhi A, Louvi A, Lifton RP, Sestan N, State MW. Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science 2005; 310: 317-320.
44. Miranda DM, Wigg K, Kabia EM, Feng Y, Sandor P, Barr CL. Association of SLITRK1 to Gilles de la Tourette syndrome. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 483-486.
45. Karagiannidis I, Rizzo R, Tarnok Z, Wolanczyk T, Hebebrand J, Nothen MM, Lehmkuhl G, Farkas L, Nagy P, Barta C, Szymanska U, Panteloglou G, Miranda DM, Feng Y, Sandor P, Barr C, TSgeneSEE, Paschou P. Replication of association between a SLITRK1 haplotype and Tourette syndrome in a large sample of families. Mol Psychiatry 2012; 17: 665-668.
46. Scharf JM, Miller LL, Mathews CA, Ben-Shlomo Y. Prevalence of Tourette syndrome and chronic tics in the population-based Avon longitudinal study of parents and children cohort. J Am Acad Child Adolesc Psychiatry 2012; 51: 192-201 e5.
47. Tourette Syndrome Association International Consortium for Genetics. Genome scan for Tourette disorder in affected-sibling-pair and multigenerational families. Am J Hum Genet 2007; 80: 265-272.
48. O'Rourke JA, Scharf JM, Yu D, Pauls DL. The genetics of Tourette syndrome: a review. J Psychosom Res 2009; 67: 533-545.
49. Swain JE, Scahill L, Lombroso PJ, King RA, Leckman JF. Tourette syndrome and tic disorders: a decade of progress. J Am Acad Child Adolesc Psychiatry 2007; 46: 947-968.
50. Bornstein RA, Stefl ME, Hammond L. A survey of Tourette syndrome patients and their families: the 1987 Ohio Tourette Survey. J Neuropsychiatry Clin Neurosci 1990; 2: 275-281.
51. Lombroso PJ, Mack G, Scahill L, King RA, Leckman JF. Exacerbation of Gilles de la Tourette's syndrome associated with thermal stress: a family study. Neurology 1991; 41: 1984-1987.
52. Nelson EC, Pribor EF. A calendar savant with autism and Tourette syndrome. Response to treatment and thoughts on the interrelationships of these conditions. Ann Clin Psychiatry 1993; 5: 135-140.
53. Silva RR, Munoz DM, Barickman J, Friedhoff AJ. Environmental factors and related fluctuation of symptoms in children and adolescents with Tourette's disorder. J Child Psychol Psychiatry 1995; 36: 305-312.
54. Conelea CA, Woods DW. The influence of contextual factors on tic expression in Tourette's syndrome: a review. J Psychosom Res 2008; 65: 487-496.
55. Conelea CA, Woods DW, Brandt BC. The impact of a stress induction task on tic frequencies in youth with Tourette Syndrome. Behav Res Ther 2011; 49: 492-497.
56. Lin H, Katsovich L, Ghebremichael M, Findley DB, Grantz H, Lombroso PJ, King RA, Zhang H, Leckman JF. Psychosocial stress predicts future symptom severities in children and adolescents with Tourette syndrome and/or obsessive-compulsive disorder. J Child Psychol Psychiatry 2007; 48: 157-166.
57. Saccomani L, Fabiana V, Manuela B, Giambattista R. Tourette syndrome and chronic tics in a sample of children and adolescents. Brain Dev 2005; 27: 349-352.
58. Motlagh MG, Katsovich L, Thompson N, Lin H, Kim YS, Scahill L, Lombroso PJ, King RA, Peterson BS, Leckman JF. Severe psychosocial stress and heavy cigarette smoking during pregnancy: an examination of the pre- and perinatal risk factors associated with ADHD and Tourette syndrome. Eur Child Adolesc Psychiatry 2010; 19: 755-764.
59. Bos-Veneman NG, Olieman R, Tobiasova Z, Hoekstra PJ, Katsovich L, Bothwell AL, Leckman JF, Kawikova I. Altered immunoglobulin profiles in children with Tourette syndrome. Brain Behav Immun 2011; 25: 532-538.
60. Leckman JF, Dolnansky ES, Hardin MT, Clubb M, Walkup JT, Stevenson J, Pauls DL. Perinatal factors in the expression of Tourette's syndrome: an exploratory study. J Am Acad Child Adolesc Psychiatry 1990; 29: 220-226.
61. Mathews CA, Bimson B, Lowe TL, Herrera LD, Budman CL, Erenberg G, Naarden A, Bruun RD, Freimer NB, Reus VI. Association between maternal smoking and increased symptom severity in Tourette's syndrome. Am J Psychiatry 2006; 163: 1066-1073.
62. Swedo SE, Leonard HL, Garvey M, Mittleman B, Allen AJ, Perlmutter S, Lougee L, Dow S, Zamkoff J, Dubbert BK. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 1998; 155: 264-271.
63. Mell LK, Davis RL, Owens D. Association between streptococcal infection and obsessive-compulsive disorder, Tourette's syndrome, and tic disorder. Pediatrics 2005; 116: 56-60.
64. Leslie DL, Kozma L, Martin A, Landeros A, Katsovich L, King RA, Leckman JF. Neuropsychiatric disorders associated with streptococcal infection: a case-control study among privately insured children. J Am Acad Child Adolesc Psychiatry 2008; 47: 1166-1172.
65. Martino D, Dale RC, Gilbert DL, Giovannoni G, Leckman JF. Immunopathogenic mechanisms in tourette syndrome: a critical review. Mov Disord 2009; 24: 1267-1279.
66. Lin H, Williams KA, Katsovich L, Findley DB, Grantz H, Lombroso PJ, King RA, Bessen DE, Johnson D, Kaplan EL, Landeros-Weisenberger A, Zhang H, Leckman JF. Streptococcal upper respiratory tract infections and psychosocial stress predict future tic and obsessive-compulsive symptom severity in children and adolescents with Tourette syndrome and obsessive-compulsive disorder. Biol Psychiatry 2010; 67: 684-691.
67. Zohar I, Weinstock M. Differential effect of prenatal stress on the expression of corticotrophin-releasing hormone and its receptors in the hypothalamus and amygdala in male and female rats. J Neuroendocrinol 2011; 23: 320-328.
68. Jankovic J, Kurlan R. Tourette syndrome: evolving concepts. Mov Disord 2011; 26: 1149-1156.
69. Santangelo SL, Pauls DL, Goldstein JM, Faraone SV, Tsuang MT, Leckman JF. Tourette's syndrome: what are the influences of gender and comorbid obsessive-compulsive disorder? J Am Acad Child Adolesc Psychiatry 1994; 33: 795-804.
70. Lichter DG. Female gender is an independent predictor of tic severity in adult Tourette syndrome. Mov Disord 2008; 23: S146-S147.
71. Baumgardner TL, Singer HS, Denckla MB, Rubin MA, Abrams MT, Colli MJ, Reiss AL. Corpus callosum morphology in children with Tourette syndrome and attention deficit hyperactivity disorder. Neurology 1996; 47: 477-482.
72. Mostofsky SH, Wendlandt J, Cutting L, Denckla MB, Singer HS. Corpus callosum measurements in girls with Tourette syndrome. Neurology 1999; 53: 1345-1347.
73. Fahim C, Yoon U, Das S, Lyttelton O, Chen J, Arnaoutelis R, Rouleau G, Sandor P, Frey K, Brandner C, Evans AC. Somatosensory-motor bodily representation cortical thinning in Tourette: effects of tic severity, age and gender. Cortex 2010; 46: 750-760.
74. Sandyk R, Bamford CR. Deregulation of hypothalamic opioid and luteinizing hormone releasing factor (LHRF) activity and its relevance to Tourette's syndrome. Int J Neurosci 1988; 39: 223-224.
75. Sandyk R, Bamford CR, Binkiewicz A, Finley PR. Gonadotropin deficiency in Tourette's syndrome: a preliminary communication. Int J Neurosci 1988; 42: 121-125.
76. Leckman JF, Scahill L. Possible exacerbation of tics by androgenic steroids. N Engl J Med 1990; 322: 1674.
77. Budman CL, Bruun RD, Park KS, Olson ME. Rage attacks in children and adolescents with Tourette's disorder: a pilot study. J Clin Psychiatry 1998; 59: 576-580.
78. Comings DE, Comings BG. A controlled study of Tourette syndrome. II. Conduct. Am J Hum Genet 1987; 41: 742-760.
79. Alexander GM, Peterson BS. Testing the prenatal hormone hypothesis of tic-related disorders: gender identity and gender role behavior. Dev Psychopathol 2004; 16: 407-420.
80. Peterson AL, Campise RL, Azrin NH. Behavioral and pharmacological treatments for tic and habit disorders: a review. J Dev Behav Pediatr 1994; 15: 430-441.
81. Peterson BS, Zhang H, Anderson GM, Leckman JF. A double-blind, placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourette's syndrome. J Clin Psychopharmacol 1998; 18: 324-331.
82. Izmir M, Dursun SM. Cyproterone acetate treatment of Tourette's syndrome. Can J Psychiatry 1999; 44: 710-711.
83. Brahm J, Brahm M, Segovia R, Latorre R, Zapata R, Poniachik J, Buckel E, Contreras L. Acute and fulminant hepatitis induced by flutamide: case series report and review of the literature. Ann Hepatol 2011; 10: 93-98.
84. Schwabe MJ, Konkol RJ. Menstrual cycle-related fluctuations of tics in Tourette syndrome. Pediatr Neurol 1992; 8: 43-46.
85. Kompoliti K, Goetz CG, Leurgans S, Raman R, Comella CL. Estrogen, progesterone, and tic severity in women with Gilles de la Tourette syndrome. Neurology 2001; 57: 1519.
86. Di Paolo T. Modulation of brain dopamine transmission by sex steroids. Rev Neurosci 1994; 5: 27-41.
87. Petitclerc M, Bedard PJ, Di Paolo T. Progesterone releases dopamine in male and female rat striatum: a behavioral and microdialysis study. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 491-497.
88. Tomas-Camardiel M, Sanchez-Hidalgo MC, Sanchez del Pino MJ, Navarro A, Machado A, Cano J. Comparative study of the neuroprotective effect of dehydroepiandrosterone and 17beta-estradiol against 1-methyl-4-phenylpyridium toxicity on rat striatum. Neuroscience 2002; 109: 569-584.
89. De Souza MM, Pereira MA, Ardenghi JV, Mora TC, Bresciani LF, Yunes RA, Delle Monache F, Cechinel-Filho V. Filicene obtained from Adiantum cuneatum interacts with the cholinergic, dopaminergic, glutamatergic, GABAergic, and tachykinergic systems to exert antinociceptive effect in mice. Pharmacol Biochem Behav 2009; 93: 40-46.
90. Tye SJ, Miller AD, Blaha CD. Differential corticosteroid receptor regulation of mesoaccumbens dopamine efflux during the peak and nadir of the circadian rhythm: a molecular equilibrium in the midbrain? Synapse 2009; 63: 982-990.
91. Sanchez MG, Bourque M, Morissette M, Di Paolo T. Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 2010; 16: e43-e71.
92. Chappell P, Leckman J, Goodman W, Bissette G, Pauls D, Anderson G, Riddle M, Scahill L, McDougle C, Cohen D. Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette's syndrome: comparison to obsessive compulsive disorder and normal controls. Biol Psychiatry 1996; 39: 776-783.
93. Leckman JF, Goodman WK, Anderson GM, Riddle MA, Chappell PB, McSwiggan-Hardin MT, McDougle CJ, Scahill LD, Ort SI, Pauls DL, Cohen DJ, Price LH. Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacology 1995; 12: 73-86.
94. Chappell P, Riddle M, Anderson G, Scahill L, Hardin M, Walker D, Cohen D, Leckman J. Enhanced stress responsivity of Tourette syndrome patients undergoing lumbar puncture. Biol Psychiatry 1994; 36: 35-43.
95. Corbett BA, Mendoza SP, Baym CL, Bunge SA, Levine S. Examining cortisol rhythmicity and responsivity to stress in children with Tourette syndrome. Psychoneuroendocrinology 2008; 33: 810-820.
96. Sandyk R, Bamford CR. Heightened cortisol response to administration of naloxone in Tourette's syndrome. Int J Neurosci 1988; 39: 225-227.
97. Dietl T, Kumpfel T, Hinze-Selch D, Trenkwalder C, Lechner C. Exacerbation of tics by prednisolone. Nervenarzt 1998; 69: 1111-1114.
98. Imperato A, Puglisi-Allegra S, Casolini P, Zocchi A, Angelucci L. Stress-induced enhancement of dopamine and acetylcholine release in limbic structures: role of corticosterone. Eur J Pharmacol 1989; 165: 337-338.
99. Piazza PV, Rougé-Pont F, Deroche V, Maccari S, Simon H, Le Moal M. Glucocorticoids have state-dependent stimulant effects on the mesencephalic dopaminergic transmission. Proc Natl Acad Sci U S A 1996; 93: 8716-8720.
100. Mensah-Nyagan AG, Kibaly C, Schaeffer V, Venard C, Meyer L, Patte-Mensah C. Endogenous steroid production in the spinal cord and potential involvement in neuropathic pain modulation. J Steroid Biochem Mol Biol 2008; 109: 286-293.
101. Mensah-Nyagan AG, Do-Régo JL, Beaujean D, Luu-The V, Pelletier G, Vaudry H. Regulation of neurosteroid biosynthesis in the frog diencephalon by GABA and endozepines. Horm Behav 2001; 40: 218-225.
102. Paba S, Frau R, Godar SC, Devoto P, Marrosu F, Bortolato M. Steroid 5alpha-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders. Curr Pharm Des 2011; 17: 151-167.
103. Barbaccia ML. Much excitement about antidepressants, DBI and c-FOS. Pharmacol Res 2011; 64: 333-335.
104. Sarkar J, Wakefield S, MacKenzie G, Moss SJ, Maguire J. Neurosteroidogenesis is required for the physiological response to stress: role of neurosteroid-sensitive GABAA receptors. J Neurosci 2011; 31: 18198-18210.
105. Castelli MP, Casti A, Casu A, Frau R, Bortolato M, Spiga S, Ennas MG. Regional distribution of 5alpha-reductase type 2 in the adult rat brain: an immunohistochemical analysis. Psychoneuroendocrinology 2013; 38: 281-293.
106. Sanchez P, Torres JM, Castro B, Olmo A, del Moral RG, Ortega E. Expression of steroid 5alpha-reductase isozymes in prostate of adult rats after environmental stress. FEBS J 2013; 280: 93-101.
107. Bortolato M, Frau R, Orru M, Bourov Y, Marrosu F, Mereu G, Devoto P, Gessa GL. Antipsychotic-like properties of 5-alpha-reductase inhibitors. Neuropsychopharmacology 2008; 33: 3146-3156.
108. Swerdlow NR, Sutherland AN. Preclinical models relevant to Tourette syndrome. Adv Neurol 2006; 99: 69-88.
109. Castellanos FX, Fine EJ, Kaysen D, Marsh WL, Rapoport JL, Hallett M. Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results. Biol Psychiatry 1996; 39: 33-41.
110. Cohen AJ, Leckman JF. Sensory phenomena associated with Gilles de la Tourette's syndrome. J Clin Psychiatry 1992; 53: 319-323.
111. Leckman JF, Peterson BS. The pathogenesis of Tourette's syndrome: epigenetic factors active in early CNS development. Biol Psychiatry 1993; 34: 425-427.
112. Miguel EC, Baer L, Coffey BJ, Rauch SL, Savage CR, O'Sullivan RL, Phillips K, Moretti C, Leckman JF, Jenike MA. Phenomenological differences appearing with repetitive behaviours in obsessive-compulsive disorder and Gilles de la Tourette's syndrome. Br J Psychiatry 1997; 170: 140-145.
113. Miguel EC, do Rosario-Campos MC, Prado HS, do Valle R, Rauch SL, Coffey BJ, Baer L, Savage CR, O'Sullivan RL, Jenike MA, Leckman JF. Sensory phenomena in obsessive-compulsive disorder and Tourette's disorder. J Clin Psychiatry 2000; 61: 150-156; quiz 7.
114. Devoto P, Frau R, Bini V, Pillolla G, Saba P, Flore G, Corona M, Marrosu F, Bortolato M. Inhibition of 5alpha-reductase in the nucleus accumbens counters sensorimotor gating deficits induced by dopaminergic activation. Psychoneuroendocrinology 2012; 37: 1630-1645.
115. Frau R, Pillolla G, Bini V, Tambaro S, Devoto P, Bortolato M. Inhibition of 5alpha-reductase attenuates behavioral effects of D1-, but not D2-like receptor agonists in C57BL/6 mice. Psychoneuroendocrinology 2013; 38: 542-551.
116. Bortolato M, Muroni A, Marrosu F. Treatment of Tourette's syndrome with finasteride. Am J Psychiatry 2007; 164: 1914-1915.
117. Muroni A, Paba S, Puligheddu M, Marrosu F, Bortolato M. A preliminary study of finasteride in Tourette syndrome. Mov Disord 2011; 26: 2146-2147.
118. Bortolato M, Cannas A, Solla P, Bini V, Puligheddu M, Marrosu F. Finasteride attenuates pathological gambling in patients with Parkinson disease. J Clin Psychopharmacol 2012; 32: 424-425.
119. Morissette J, Durocher F, Leblanc JF, Normand T, Labrie F, Simard J. Genetic linkage mapping of the human steroid 5 alpha-reductase type 2 gene (SRD5A2) close to D2S352 on chromosome region 2p23->p22. Cytogenet Cell Genet 1996; 73: 304-307.
120. Barr CL, Wigg KG, Pakstis AJ, Kurlan R, Pauls D, Kidd KK, Tsui LC, Sandor P. Genome scan for linkage to Gilles de la Tourette syndrome. Am J Med Genet 1999; 88: 437-445.
121. Curtis D, Brett P, Dearlove AM, McQuillin A, Kalsi G, Robertson MM, Gurling HM. Genome scan of Tourette syndrome in a single large pedigree shows some support for linkage to regions of chromosomes 5, 10 and 13. Psychiatr Genet 2004; 14: 83-87.
122. Schmidtova E, Kelemenova S, Celec P, Ficek A, Ostatnikova D. Polymorphisms in genes involved in testosterone metabolism in Slovak autistic boys. Endocrinologist 2010; 20: 245-249.
123. Steen NE, Tesli M, Kahler AK, Methlie P, Hope S, Barrett EA, Larsson S, Mork E, Lovas K, Rossberg JI, Agartz I, Melle I, Djurovic S, Lorentzen S, Berg JP, Andreassen OA. SRD5A2 is associated with increased cortisol metabolism in schizophrenia spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1500-1506.
124. Steen NE, Methlie P, Lorentzen S, Hope S, Barrett EA, Larsson S, Mork E, Almas B, Lovas K, Agartz I, Melle I, Berg JP, Andreassen OA. Increased systemic cortisol metabolism in patients with schizophrenia and bipolar disorder: a mechanism for increased stress vulnerability? J Clin Psychiatry 2011; 72: 1515-1521.
125. Mapes S, Corbin CJ, Tarantal A, Conley A. The primate adrenal zona reticularis is defined by expression of cytochrome b5, 17alpha-hydroxylase/17, 20-lyase cytochrome P450 (P450c17) and NADPH-cytochrome P450 reductase (reductase) but not 3beta-hydroxysteroid dehydrogenase/delta5-4 isomerase (3beta-HSD). J Clin Endocrinol Metab 1999; 84: 3382-3385.
126. Katagiri M, Kagawa N, Waterman MR. The role of cytochrome b5 in the biosynthesis of androgens by human P450c17. Arch Biochem Biophys 1995; 317: 343-347.
127. Zhang LH, Rodriguez H, Ohno S, Miller WL. Serine phosphorylation of human P450c17 increases 17, 20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci USA 1995; 92: 10619-10623.
128. Auchus RJ, Lee TC, Miller WL. Cytochrome b5 augments the 17, 20-lyase activity of human P450c17 without direct electron transfer. J Biol Chem 1998; 273: 3158-3165.
129. Geller DH, Auchus RJ, Miller WL. P450c17 mutations R347H and R358Q selectively disrupt 17, 20-lyase activity by disrupting interactions with P450 oxidoreductase and cytochrome b5. Mol Endocrinol 1999; 13: 167-175.
130. Biason-Lauber A, Kempken B, Werder E, Forest MG, Einaudi S, Ranke MB, Matsuo N, Brunelli V, Schonle EJ, Zachmann M. 17alpha-hydroxylase/17, 20-lyase deficiency as a model to study enzymatic activity regulation: role of phosphorylation. J Clin Endocrinol Metab 2000; 85: 1226-1231.
131. Pattison JC, Saltzman W, Abbott DH, Hogan BK, Nguyen AD, Husen B, Einspanier A, Conley AJ, Bird IM. Gender and gonadal status differences in zona reticularis expression in marmoset monkey adrenals: cytochrome b5 localization with respect to cytochrome P450 17, 20-lyase activity. Mol Cell Endocrinol 2007; 265-266.
132. Nguyen AD, Corbin CJ, Pattison JC, Bird IM, Conley AJ. The developmental increase in adrenocortical 17, 20-lyase activity (biochemical adrenarche) is driven primarily by increasing cytochrome b5 in neonatal rhesus macaques. Endocrinology 2009; 150: 1748-1756.
133. Auchus RJ, Rainey WE. Adrenarche - physiology, biochemistry and human disease. Clin Endocrinol (Oxf) 2004; 60: 288-296.
134. Fluck CE, Miller WL, Auchus RJ. The 17, 20-lyase activity of cytochrome p450c17 from human fetal testis favors the delta5 steroidogenic pathway. J Clin Endocrinol Metab 2003; 88: 3762-3766.
135. Gupta MK, Guryev OL, Auchus RJ. 5alpha-reduced C21 steroids are substrates for human cytochrome P450c17. Arch Biochem Biophys 2003; 418: 151-160.
136. Auchus RJ. Overview of dehydroepiandrosterone biosynthesis. Semin Reprod Med 2004; 22: 281-288.
137. Kamrath C, Hartmann MF, Remer T, Wudy SA. The activities of 5alpha-reductase and 17, 20-lyase determine the direction through androgen synthesis pathways in patients with 21-hydroxylase deficiency. Steroids 2012; 77: 1391-1397.
138. Kamrath C, Hochberg Z, Hartmann MF, Remer T, Wudy SA. Increased activation of the alternative 'backdoor' pathway in patients with 21-hydroxylase deficiency: evidence from urinary steroid hormone analysis. J Clin Endocrinol Metab 2012; 97: E367-E375.
139. Eckstein B, Borut A, Cohen S. Metabolic pathways for androstanediol formation in immature rat testis microsomes. Biochim Biophys Acta 1987; 924: 1-6.
140. Mueller SC, Ng P, Sinaii N, Leschek EW, Green-Golan L, VanRyzin C, Ernst M, Merke DP. Psychiatric characterization of children with genetic causes of hyperandrogenism. Eur J Endocrinol 2010; 163: 801-810.
141. Yu L, Romero DG, Gomez-Sanchez CE, Gomez-Sanchez EP. Steroidogenic enzyme gene expression in the human brain. Mol Cell Endocrinol 2002; 190: 9-17.
142. Stoffel-Wagner B, Watzka M, Steckelbroeck S, Schramm J, Bidlingmaier JF, Klingmuller D. Expression of 17beta-hydroxysteroid dehydrogenase types 1, 2, 3 and 4 in the human temporal lobe. J Endocrinol 1999; 160: 119-126.
143. Steckelbroeck S, Watzka M, Reissinger A, Wegener-Toper P, Bidlingmaier F, Bliesener N, Hans VH, Clusmann H, Ludwig M, Siekmann L, Klingmuller D. Characterisation of estrogenic 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity in the human brain. J Steroid Biochem Mol Biol 2003; 86: 79-92.
144. Compagnone NA, Bulfone A, Rubenstein JL, Mellon SH. Steroidogenic enzyme P450c17 is expressed in the embryonic central nervous system. Endocrinology 1995; 136: 5212-5223.
145. Pelletier G, Luu-The V, Labrie F. Immunocytochemical localization of type I 17 beta-hydroxysteroid dehydrogenase in the rat brain. Brain Res 1995; 704: 233-239.
146. Mensah-Nyagan AM, Feuilloley M, Do-Rego JL, Marcual A, Lange C, Tonon MC, Pelletier G, Vaudry H. Localization of 17beta-hydroxysteroid dehydrogenase and characterization of testosterone in the brain of the male frog. Proc Natl Acad Sci USA 1996; 93: 1423-1428.
147. Zwain IH, Yen SS. Neurosteroidogenesis in astrocytes, oligodendrocytes, and neurons of cerebral cortex of rat brain. Endocrinology 1999; 140: 3843-3852.
148. Matsunaga M, Ukena K, Tsutsui K. Expression and localization of cytochrome P450 17 alpha-hydroxylase/c17, 20-lyase in the avian brain. Brain Res 2001; 899: 112-122.
149. Halm S, Kwon JY, Rand-Weaver M, Sumpter JP, Pounds N, Hutchinson TH, Tyler CR. Cloning and gene expression of P450 17alpha-hydroxylase, 17, 20-lyase cDNA in the gonads and brain of the fathead minnow Pimephales promelas. Gen Comp Endocrinol 2003; 130: 256-266.
150. Ogundare M, Theofilopoulos S, Lockhart A, Hall LJ, Arenas E, Sjovall J, Brenton AG, Wang Y, Griffiths WJ. Cerebrospinal fluid steroidomics: are bioactive bile acids present in brain? J Biol Chem 2010; 285: 4666-4679.
151. Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med 2011; 8: 872-884.
152. Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med 2011; 8: 1747-1753.
153. Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry 2012; 73: 1220-1223.
154. Burton FH, Hasel KW, Bloom FE, Sutcliffe JG. Pituitary hyperplasia and gigantism in mice caused by a cholera toxin transgene. Nature 1991; 350: 74-77.
155. Campbell KM, de Lecea L, Severynse DM, Caron MG, McGrath MJ, Sparber SB, Sun LY, Burton FH. OCD-Like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1 + neurons. J Neurosci 1999; 19: 5044-5053.
156. Nordstrom EJ, Burton FH. A transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry. Mol Psychiatry 2002; 7: 617-625, 524.
157. McGrath MJ, Campbell KM, Parks CR, Burton FH. Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder. Brain Res 2000; 877: 23-30.
158. Pignatelli D, Xiao F, Gouveia AM, Ferreira JG, Vinson GP. Adrenarche in the rat. J Endocrinol 2006; 191: 301-308.
159. Comings DE, Wu S, Chiu C, Ring RH, Gade R, Ahn C, MacMurray JP, Dietz G, Muhleman D. Polygenic inheritance of Tourette syndrome, stuttering, attention deficit hyperactivity, conduct, and oppositional defiant disorder: the additive and subtractive effect of the three dopaminergic genes - DRD2, D beta H, and DAT1. Am J Med Genet 1996; 67: 264-288.
160. Diaz-Anzaldua A, Joober R, Riviere JB, Dion Y, Lesperance P, Richer F, Chouinard S, Rouleau GA, Montreal Tourette Syndrome Study Group. Tourette syndrome and dopaminergic genes: a family-based association study in the French Canadian founder population. Mol Psychiatry 2004; 9: 272-277.
161. Tarnok Z, Ronai Z, Gervai J, Kereszturi E, Gadoros J, Sasvari-Szekely M, Nemoda Z. Dopaminergic candidate genes in Tourette syndrome: association between tic severity and 3' UTR polymorphism of the dopamine transporter gene. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 900-905.
162. Ercan-Sencicek AG, Stillman AA, Ghosh AK, Bilguvar K, O'Roak BJ, Mason CE, Abbott T, Gupta A, King RA, Pauls DL, Tischfield JA, Heiman GA, Singer HS, Gilbert DL, Hoekstra PJ, Morgan TM, Loring E, Yasuno K, Fernandez T, Sanders S, Louvi A, Cho JH, Mane S, Colangelo CM, Biederer T, Lifton RP, Gunel M, State MW. L-histidine decarboxylase and Tourette's syndrome. N Engl J Med 2010; 362: 1901-1908.
163. Lawson-Yuen A, Saldivar JS, Sommer S, Picker J. Familial deletion within NLGN4 associated with autism and Tourette syndrome. Eur J Hum Genet 2008; 16: 614-618.
164. Verkerk AJ, Mathews CA, Joosse M, Eussen BH, Heutink P, Oostra BA, Tourette Syndrome Association International Consortium for G. CNTNAP2 is disrupted in a family with Gilles de la Tourette syndrome and obsessive compulsive disorder. Genomics 2003; 82: 1-9.
165. Boghosian-Sell L, Comings DE, Overhauser J. Tourette syndrome in a pedigree with a 7;18 translocation: identification of a YAC spanning the translocation breakpoint at 18q22.3. Am J Hum Genet 1996; 59: 999-1005.